
T-Therapeutics raises $133M to advance novel TCR bispecific therapies for cancer and autoimmune diseases
T-Therapeutics secured $133 million in an oversubscribed Series B funding round led by Advent Life Sciences and British Business Bank to develop its first-in-class TCR-CD3 bispecific therapies targeting cancer and autoimmune diseases. The funds will ...





